Cullinan Oncology, Inc. (CGEM)
Largest Insider Buys in Sector
CGEM Stock Price History Chart
CGEM Stock Performance
About Cullinan Oncology, Inc.
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of …
Insider Activity of Cullinan Oncology, Inc.
Over the last 12 months, insiders at Cullinan Oncology, Inc. have bought $0 and sold $4.03M worth of Cullinan Oncology, Inc. stock.
On average, over the past 5 years, insiders at Cullinan Oncology, Inc. have bought $19.31M and sold $8.72M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 8,090 shares for transaction amount of $100,316 was made by AHMED NADIM (President and CEO) on 2022‑06‑06.
List of Insider Buy and Sell Transactions, Cullinan Oncology, Inc.
| 2024-11-05 | Sale | Chief Scientific Officer | 8,000 0.0134% | $15.64 | $125,120 | -2.73% | ||
| 2024-09-05 | Sale | Chief Scientific Officer | 8,000 0.0139% | $18.09 | $144,720 | -8.09% | ||
| 2024-07-05 | Sale | Chief Scientific Officer | 8,000 0.0137% | $16.33 | $130,640 | 0.00% | ||
| 2024-05-07 | Sale | Chief Scientific Officer | 5,606 0.0138% | $30.06 | $168,516 | -38.99% | ||
| 2024-05-06 | Sale | Chief Scientific Officer | 58,000 0.1331% | $28.07 | $1.63M | -36.87% | ||
| 2024-02-01 | Sale | Chief Business Officer | 40,000 0.104% | $16.18 | $647,200 | +1.46% | ||
| 2024-01-29 | Sale | Chief Business Officer | 40,000 0.0901% | $14.09 | $563,600 | +21.24% | ||
| 2024-01-23 | Sale | Chief Business Officer | 21,316 0.0493% | $12.46 | $265,597 | +40.89% | ||
| 2024-01-22 | Sale | Chief Business Officer | 18,684 0.0431% | $12.14 | $226,911 | +44.21% | ||
| 2023-12-26 | Sale | President and CEO | 4,272 0.0096% | $9.24 | $39,473 | +80.81% | ||
| 2023-12-21 | Sale | Chief Scientific Officer | 1,145 0.0024% | $8.50 | $9,733 | +82.97% | ||
| 2023-12-21 | Sale | Chief Financial Officer | 1,920 0.004% | $8.50 | $16,320 | +82.97% | ||
| 2023-12-21 | Sale | Chief Medical Officer | 1,860 0.0039% | $8.50 | $15,810 | +82.97% | ||
| 2023-12-21 | Sale | Chief Legal Officer | 1,400 0.0029% | $8.50 | $11,900 | +82.97% | ||
| 2023-12-18 | Sale | Chief Scientific Officer | 238 0.0005% | $8.22 | $1,956 | +91.09% | ||
| 2023-12-18 | Sale | Chief Financial Officer | 398 0.0008% | $8.22 | $3,272 | +91.09% | ||
| 2023-12-18 | Sale | Chief Medical Officer | 386 0.0008% | $8.22 | $3,173 | +91.09% | ||
| 2023-12-18 | Sale | Chief Legal Officer | 290 0.0006% | $8.22 | $2,384 | +91.09% | ||
| 2023-12-12 | Sale | Chief Scientific Officer | 1,068 0.0025% | $7.81 | $8,341 | +119.97% | ||
| 2023-12-12 | Sale | Chief Financial Officer | 1,926 0.0045% | $7.81 | $15,042 | +119.97% |
Insider Historical Profitability
| AHMED NADIM | President and CEO | 111550 0.1916% | $12.30 | 1 | 5 | <0.0001% |
| Trigilio Jeffrey | Chief Financial Officer | 83919 0.1441% | $12.30 | 1 | 12 | <0.0001% |
| UBS Oncology Impact Fund L.P. | 10 percent owner | 7648268 13.1351% | $12.30 | 1 | 18 | <0.0001% |
| LAMPERT MARK N | 4058854 6.9707% | $12.30 | 3 | 0 | +15.29% | |
| Jovan-Embiricos Morana | 1281952 2.2016% | $12.30 | 1 | 3 | <0.0001% |
Institutional Investor Ownership
| Bioimpact Capital Llc | $130.33M | 13.27 | 7.65M | 0% | +$0 | 21.09 | |
| Bvf Inc Il | $54.47M | 5.55 | 3.2M | 0% | +$0 | 0.4 | |
| Blue Owl Capital Holdings Lp | $49.84M | 5.08 | 2.92M | -14.47% | -$8.43M | 4.17 | |
| Franklin Templeton Investments | $45.95M | 4.68 | 2.7M | -17.81% | -$9.96M | 0.01 | |
| BlackRock | $41.39M | 4.21 | 2.43M | -1.35% | -$567,108.26 | <0.01 |